Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
March 03 2025 - 11:46AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of March 2025
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Issued: 3 March 2025, London UK
GSK plc 2024 Annual Report on Form 20-F
In accordance with Section 203.01 of the New York Stock Exchange
Listed Company Manual, GSK plc ("GSK") announces that on 3 March
2025 it filed with the Securities and Exchange Commission an Annual
Report on Form 20-F that included audited financial statements for
the year ended 31 December 2024. GSK's 2024 Annual Report on Form
20-F is available online at GSK's website at: https://annualreport.gsk.com and
also online at www.sec.gov.
A hard copy version of the GSK 2024 Annual Report, together with
the Notice of Annual General Meeting, will be available on or about
24 March 2025.
Shareholders have the ability to receive, upon request, a hard copy
version of GSK's complete audited financial statements for the year
ended 31 December 2024, free of charge, by either:
|
(i)
|
writing
to Computershare Investor Services, our registrars in the UK, at
the following address: Computershare Investor Services, The
Pavilions, Bridgwater Road, Bristol BS13 8AE, United Kingdom, or by
telephone on +44 (0) 370 707 1595 (please use the country code if
calling from outside the UK);
|
|
(ii)
|
writing
to J.P. Morgan Chase Bank, N.A. our ADR depositary in the US, at
the following address: EQ Shareowner Services, P.O. Box 64504, St.
Paul, MN 55164-0504, or by telephone on +1 877 353 1154 (US toll
free) or +1 651 453 2128 (outside the US); or
|
|
(iii)
|
contacting
the GSK Response Center in the USA at +1 888 825 5249 (US toll
free).
|
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at gsk.com.
Victoria Whyte
Company Secretary
3 March 2025
Cautionary statement regarding forward-looking
statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described under Item 3.D
"Risk factors" in GSK's Annual Report on Form 20-F for
2024.
Registered in England & Wales:
No.
3888792
Registered Office:
79
New Oxford Street
London
WC1A
1DG
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: March
03, 2025
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|
GSK (PK) (USOTC:GLAXF)
Historical Stock Chart
From Feb 2025 to Mar 2025
GSK (PK) (USOTC:GLAXF)
Historical Stock Chart
From Mar 2024 to Mar 2025
